In a nutshell This study compared the safety and effectiveness of different doses of an oral insulin capsule formulation (Capsulin™) to patients with early-stage type 2 diabetes (T2D). The data showed that twice-daily, orally administered Capsulin at a dose of 150 international units (IU) was safe and resulted in a significant lowering...
Read MoreDiabetes medication(s)-Non-insulin oral drugs Posts on Medivizor
Can teneligliptin be safely and effectively given to patients with inadequately controlled type 2 diabetes by triple oral antidiabetic drug treatment?
In a nutshell This study compared the effectiveness and safety of teneligliptin (Tenelia) to placebo in patients with type 2 diabetes (T2D) that was inadequately controlled with triple oral antidiabetic drugs (OADs). The study showed that teneligliptin may be considered as a fourth add-on OAD treatment in these patients. Some background T2D is...
Read MoreComparing the effects of a ketogenic diet app versus a calorie restricted, low-fat diet on weight loss in patients with overweight or obesity.
In a nutshell This study compared the effects of a ketogenic diet mobile health application (Keyto app) with breath acetone biofeedback (device) versus a calorie-restricted, low-fat diet (WW; weight watchers) app on weight loss and metabolic risk in patients with overweight or obesity. The data showed that a ketogenic diet app with a breath acetone...
Read MoreComparing chiglitazar and sitagliptin effectiveness on glucose variations, insulin resistance and inflammation levels in patients with type 2 diabetes.
In a nutshell This study compared the effectiveness of chiglitazar (Bilessglu) and sitagliptin (Januvia) on glycemic (blood glucose) variations, insulin resistance, and inflammation levels in patients with type 2 diabetes (T2D). The data showed that chiglitazar treatment was more effective at improving insulin resistance and inflammation compared...
Read MoreCan SGLT2 inhibitors prevent liver disease for people with diabetes?
In a nutshell This review looked at whether sodium-glucose cotransporter 2 (SGLT2) inhibitors can improve non-alcoholic fatty liver disease (NAFLD) for people with type 2 diabetes (T2D). It found that these medications can improve liver function in these patients. Some background NAFLD is a condition in which fat builds up in the liver. This makes the...
Read MoreReduced risk of heart failure hospitalizations in patients with type 2 diabetes using SGLT-2 inhibitors
In a nutshell This review focused on the effect of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) on heart failure hospitalization in patients with type 2 diabetes (T2D). This analysis showed that SGLT-2is may reduce the risk of heart failure hospitalizations in these patients. Some background Patients with T2D have a higher risk of developing...
Read MoreDo SGLT2 inhibitors with or without metformin improve heart and kidney health?
In a nutshell This review looked at how SGTL2 inhibitors with or without metformin (Glucophage) affect heart and kidney health for patients with type 2 diabetes (T2D). It found that these medications improve cardiovascular and kidney outcomes, whether or not patients are also taking metformin. Some background SGLT2 inhibitors are a group of T2D...
Read MoreWhich diabetic medications are least likely to cause heart disease?
In a nutshell This study examined the risk of major heart complications in patients taking a type of diabetic medication called DPP4-inhibitors. They found that patients taking DPP4-inhibitors were less likely to develop major heart disease than patients taking sulfonylureas. Some background Patients with type 2 diabetes (T2D) are at risk...
Read MoreEvaluating the safety and effectiveness of polyethylene glycol loxenatide in patients with T2D
In a nutshell This study examined the effectiveness and risks of polyethylene glycol loxenatide (PEX168) as an add-on to metformin (Glucophage) therapy in patients with type 2 diabetes (T2D). It found that PEX168 is safe and works effectively in improving the blood sugar levels in these patients. Some background T2D is a...
Read MoreEvaluating combination therapy versus metformin only for patients with Type 2 diabetes
In a nutshell This study evaluated whether adding vildagliptin (Galvus) to metformin (Glucophage) could improve the duration of blood glucose control for patients with newly diagnosed Type 2 Diabetes (T2D). The authors found that this treatment combination improved long-term blood glucose control for these patients. Some background...
Read MoreIs IDegLira more effective than degludec or liraglutide alone for treating uncontrolled Type 2 diabetes?
In a nutshell This study compared IDegLira (Xultophy) to insulin degludec (Tresiba) or liraglutide (Victoza) alone in patients with uncontrolled Type 2 diabetes (T2D). The authors concluded that combined IDegLira was more effective and had fewer side effects than either insulin medication alone. Some background One of the main...
Read MoreIs IDegLira more effective than standard insulin for patients with Type 2 diabetes?
In a nutshell This study compared insulin degludec/liraglutide (IDegLira) to standard insulin in patients with uncontrolled Type 2 diabetes (T2D). The authors concluded that IDegLira improved patient compliance to treatment and reduced treatment-related stress compared to conventional insulin. Some background One of the main goals of treatment...
Read More